SCHEMBL3496417

SCHEMBL3496417

Cc1cnc(Nc2ccc(S(N)(=O)=O)cc2)nc1NC1CC(C)(C)N(C)C(C)(C)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.53
CDK2 P24941 6/20 0.50
CCNA2 P20248 1/20 0.50
CCNE1 P24864 4/20 0.49
JAK1 P23458 3/20 0.48
JAK3 P52333 2/20 0.48
CA2 P00918 2/20 0.47
CA1 P00915 1/20 0.47
CA4 P22748 1/20 0.47
CA9 Q16790 1/20 0.47
STK4 Q13043 6/20 0.46
CCNT1 O60563 2/20 0.46
CCNB2 O95067 2/20 0.46
CCNE2 O96020 2/20 0.46
CDK1 P06493 2/20 0.46
CCNB1 P14635 2/20 0.46
CDK9 P50750 2/20 0.46
CDK5 Q00535 2/20 0.46
CDK5R1 Q15078 2/20 0.46
CCNB3 Q8WWL7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3493447 0.89 CDK2 (0.55) SYKCDK2CCNA2CCNE1CA2
SCHEMBL3493742 0.89 JAK3 (0.58) SYKCDK2CCNA2CCNE1JAK1
SCHEMBL3493343 0.88 BRD4 (0.48) SYKCDK2JAK1JAK3CDK1
SCHEMBL3494931 0.80 PRKCQ (0.54) SYKCDK2CCNA2CCNE1JAK3
SCHEMBL3494857 0.80 PRKCQ (0.50) SYKJAK1JAK3
SCHEMBL3495796 0.78 CDK2 (0.58) CDK2CCNA2CCNE1JAK1JAK3
SCHEMBL3494248 0.77 BRD4 (0.58) SYK
SCHEMBL3494481 0.76 PRKCQ (0.63) SYKJAK1JAK3
SCHEMBL3496651 0.76 BCL6 (0.52)
SCHEMBL3494605 0.76 BRD4 (0.47) SYKCDK2CCNA2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ SYK 460/4885CDK2 129/4885CCNA2 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.